Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Vivos Therapeutics Inc
VVOS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.1347
-0.0059
-4.2%
Últ. Act.: Oct 21, 4:44 PM
$0.1337
-0.0069
-4.91%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Fusiones y adquisiciones:
SOD Sciences, Inc. was acquired by Vivos Therapeutics (VVOS) on Monday, October 19, 2026 for $12M
Vivos Therapeutics Financials
Vivos Therapeutics (VVOS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share
Benzinga Newsdesk
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.
Avi Kapoor
PRO
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
Benzinga Newsdesk
